Vaccine formulation and delivery device

September 2004
WHO Technical Report Series;2004, Issue 927, p52
Academic Journal
The article presents the section of the World Health Organization guidelines on nonclinical evaluation of vaccines concerning vaccine formulation and the delivery device. The delivery device and vaccine development whether in liquid form, capsules or powder, can have an affect on the process of vaccine formulation, its effectiveness and safety. The section also stated that it is ideal for the delivery device and vaccine formulation used in animal testing be the same to those intended to be used in clinical trials.


Related Articles

  • Additives (excipients and preservatives).  // WHO Technical Report Series;2004, Issue 927, p52 

    The article presents the section of the World Health Organization guidelines on nonclinical evaluation of vaccines concerning additives. In case where a new additive is to be applied on vaccine clinical investigation, there is a need to perform first toxicity studies of the additive alone and it...

  • Statement on publishing clinical trials in Indian biomedical journals. Satyanarayana, K.; Sharma, A.; Parikh, P.; Vijayan, V. K.; Sahu, D. K.; Nayak, B. K.; Gulati, R. K.; Parikh, M. N.; Singh, P. P.; Bavdekar, S. B.; Sreehari, U.; Sahni, P. // Indian Journal of Cancer;Apr-Jun2008, Vol. 45 Issue 2, p39 

    The article focuses on the launching of Clinical Trial Registry India in New Delhi on July 20, 2007. The launching of the online registry was hosted by the National Institute of Medical Statistics (NIMS) and the Indian Council of Medical Research (ICMR). The online registry was established to...

  • WHO calls for full disclosure of clinical trials. Woolston, Chris // Nature;4/23/2015, Vol. 520 Issue 7548, p411 

    The article reports that the World Health Organization (WHO) has called for full disclosure of clinical-trial results in biomedical research.

  • Basic toxicity assessment.  // WHO Technical Report Series;2004, Issue 927, p45 

    The article discusses the World Health Organization guidelines in evaluating the potential toxic effects of a vaccine. The guidelines specified the parameters relevant in designing animal toxicology studies. It clarified that the potential effects of the product should be evaluated with regard...

  • News In Brief.  // Nature Medicine;Jul2004, Vol. 10 Issue 7, p658 

    Presents news briefs related to medicine. Endorsement by the Group of Eight (G8) industrialized nations for a global HIV vaccine enterprise; Endorsement of a Global Strategy on Diet by member states of the World Health Organization in response to the obesity epidemic; Recommendation by the...

  • Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children. Owusu-Agyei, Seth; Ansong, Daniel; Asante, Kwaku; Owusu, Sandra Kwarteng; Owusu, Ruth; Brobby, Naana Ayiwa Wireko; Dosoo, David; Akoto, Alex Osei; Osei-Kwakye, Kingsley; Adjei, Emmanuel Asafo; Boahen, Kwadwo Owusu; Sylverken, Justice; Adjei, George; Sambian, David; Apanga, Stephen; Kayan, Kingsley; Vekemans, Johan; Ofori-Anyinam, Opokua; Leach, Amanda; Lievens, Marc // PLoS ONE;2009, Vol. 4 Issue 10, p1 

    Background: The target delivery channel of RTS,S candidate malaria vaccines in malaria-endemic countries in Africa is the World Health Organisation Expanded Program on Immunization. As an Adjuvant System, age de-escalation and schedule selection step, this study assessed 3 schedules of...

  • What are the Current Advances Regarding HIV Vaccines and HIV Vaccine Trials? Dhalla, Shayesta // Journal of Bioanalysis & Biomedicine;2012, Vol. 4 Issue 3, p1 

    The author discusses the current advances on HIV vaccines around the world. She offers her views on the unsuccessful STEP study, a clinical trial which tested the efficacy of an HIV vaccine. The STEP study was stopped in 2007, which revealed an increase in HIV infection for the first 18 months...

  • Postlicensure Safety Surveillance for 7-Valent Pneumococcal Conjugate Vaccine. Wise, Robert P.; Iskander, John; Pratt, R. Douglas; Campbell, Scott; Ball, Robert; Pless, Robert P.; Braun, M. Miles // JAMA: Journal of the American Medical Association;10/13/2004, Vol. 292 Issue 14, p1702 

    Context Clinical trials evaluate a vaccine’s safety before approval, but some risks may escape detection or adequate characterization until larger population exposures occur after licensure. Objective To summarize reports of events occurring after vaccination with 7-valent pneumococcal...

  • Adverse events monitoring as a routine component of vaccine clinical trials: Evidence from the... Mayans, Marti Vall; Robertson, Susan E. // Bulletin of the World Health Organization;2000, Vol. 78 Issue 9, p1166 

    Reports on the use of the World Health Organization (WHO) Vaccine Trial Registry to assess whether and how investigators are monitoring adverse events following immunization (AEFI) in vaccine trials. Objective of the WHO Immunization Safety Priority; AEFI according to reports; Points for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics